Effects of tumor treating fields (TTFields) on glioblastoma cells are augmented by mitotic checkpoint inhibition
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource
- Language
-
Englisch
- Bibliographic citation
-
In: Cell Death Discovery (2018) 4:77. https://doi.org/10.1038/s41420-018-0079-9
- Event
-
Veröffentlichung
- (where)
-
Würzburg
- (who)
-
Universität Würzburg
- (when)
-
2024
- Creator
-
Kessler, Almuth F.
Frömbling, Greta E.
Gross, Franziska
Hahn, Mirja
Dzokou, Wilfrid
Ernestus, Ralf-Ingo
Löhr, Mario
Hagemann, Carsten
- DOI
-
10.1038/s41420-018-0079-9
- URN
-
urn:nbn:de:bvb:20-opus-325744
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
25.03.2025, 1:53 PM CET
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Kessler, Almuth F.
- Frömbling, Greta E.
- Gross, Franziska
- Hahn, Mirja
- Dzokou, Wilfrid
- Ernestus, Ralf-Ingo
- Löhr, Mario
- Hagemann, Carsten
- Universität Würzburg
Time of origin
- 2024
Other Objects (12)
Targeted therapy to overcome the blood-brain barrier in treating Glioblastoma
The role of the mitotic spindle checkpoint in chemotherapy-induced apoptosis
Molecular characterisation of Mck1, a novel Spindle Position Checkpoint (SPOC) protein and mitotic inhibitor.
Mechanistic insights into the mitotic checkpoint through biochemical characterisation and in vivo method development
First report of tumor treating fields (TTFields) therapy for glioblastoma in comorbidity with multiple sclerosis
Cell cycle-dependent cytotoxicity and mitotic spindle checkpoint dependency of investigational and approved antimitotic agents
Human Mps1 kinase is required for the mitotic spindle checkpoint, but not for centrosome duplication
Crosslink between Temozolomide and PD-L1 immune-checkpoint inhibition in glioblastoma multiforme
Genes in prolactin pathway and mitotic checkpoint as low penetrant risk factores for familial breast cancer
Smac mimetics synergize with immune checkpoint inhibitors to promote tumour immunity against glioblastoma
Glioblastoma-derived three-dimensional ex vivo models to evaluate effects and efficacy of Tumor Treating Fields (TTFields)
Nitric oxide released from JS-K induces cell death by mitotic catastrophe as part of necrosis in glioblastoma multiforme
Targeted therapy to overcome the blood-brain barrier in treating Glioblastoma
The role of the mitotic spindle checkpoint in chemotherapy-induced apoptosis
Molecular characterisation of Mck1, a novel Spindle Position Checkpoint (SPOC) protein and mitotic inhibitor.
Mechanistic insights into the mitotic checkpoint through biochemical characterisation and in vivo method development
First report of tumor treating fields (TTFields) therapy for glioblastoma in comorbidity with multiple sclerosis
Cell cycle-dependent cytotoxicity and mitotic spindle checkpoint dependency of investigational and approved antimitotic agents
Human Mps1 kinase is required for the mitotic spindle checkpoint, but not for centrosome duplication
Crosslink between Temozolomide and PD-L1 immune-checkpoint inhibition in glioblastoma multiforme
Genes in prolactin pathway and mitotic checkpoint as low penetrant risk factores for familial breast cancer
Smac mimetics synergize with immune checkpoint inhibitors to promote tumour immunity against glioblastoma
Glioblastoma-derived three-dimensional ex vivo models to evaluate effects and efficacy of Tumor Treating Fields (TTFields)
Nitric oxide released from JS-K induces cell death by mitotic catastrophe as part of necrosis in glioblastoma multiforme
Targeted therapy to overcome the blood-brain barrier in treating Glioblastoma
The role of the mitotic spindle checkpoint in chemotherapy-induced apoptosis
Molecular characterisation of Mck1, a novel Spindle Position Checkpoint (SPOC) protein and mitotic inhibitor.
Mechanistic insights into the mitotic checkpoint through biochemical characterisation and in vivo method development
First report of tumor treating fields (TTFields) therapy for glioblastoma in comorbidity with multiple sclerosis
Cell cycle-dependent cytotoxicity and mitotic spindle checkpoint dependency of investigational and approved antimitotic agents
Human Mps1 kinase is required for the mitotic spindle checkpoint, but not for centrosome duplication
Crosslink between Temozolomide and PD-L1 immune-checkpoint inhibition in glioblastoma multiforme
Genes in prolactin pathway and mitotic checkpoint as low penetrant risk factores for familial breast cancer
Smac mimetics synergize with immune checkpoint inhibitors to promote tumour immunity against glioblastoma
Glioblastoma-derived three-dimensional ex vivo models to evaluate effects and efficacy of Tumor Treating Fields (TTFields)